Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial
T helper (Th)1 insufficiency was recently found to be related to the pathogenesis of pemphigus vulgaris (PV). Decreased Th1 response was particularly noticed in the early stages of PV. Therefore, administration of interferon alpha in the early stages of aggressive PV may lead to rapid control of the...
Gespeichert in:
| Veröffentlicht in: | Archives of Dermatological Research 2015-05, Vol.307 (4), p.299-307 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 4 |
| container_start_page | 299 |
| container_title | Archives of Dermatological Research |
| container_volume | 307 |
| creator | El-Darouti, Mohammad A. Hegazy, Rehab A. Abdel Hay, Rania M. El Hawary, Marwa S. Tawdy, Amira M. Fawzy, Marwa M. Rashed, Laila A. |
| description | T helper (Th)1 insufficiency was recently found to be related to the pathogenesis of pemphigus vulgaris (PV). Decreased Th1 response was particularly noticed in the early stages of PV. Therefore, administration of interferon alpha in the early stages of aggressive PV may lead to rapid control of the acute stage of the disease. Our aim was to evaluate the role of interferon alpha in the treatment of PV. 30 patients with acute severe PV (>60 % affection) and 30 age and sex-matched healthy subjects were included in this RCT. Patients were randomly divided into two groups (A and B). Group B patients received interferon retard (one subcutaneous injection/week for 4 weeks) in addition to our protocol for the treatment of PV (systemic pulse corticosteroids/cyclophosphamide in combination with sulphasalazine and pentoxifylline) that was administered to all the included patients. IFN-γ and IL-4 were estimated by ELISA before treatment, after 4 weeks and at the end of the study duration (12 weeks). Clinical assessment was done by PAAS on a biweekly basis. All PV patients showed significantly (
P
|
| doi_str_mv | 10.1007/s00403-014-1522-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687670252</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1687670252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-57438d040e327caeadf7865e28b877d7c36af151b1bbb86a9eac126599a058ed3</originalsourceid><addsrcrecordid>eNqNksuKFDEUhoMoTtPOA7iRgBs3pblUkip3MowXGHDhCO6KVHKqO006KZPUQPtwPpsperwgCGaTnJwv_zlJfoSeUvKSEqJeZUJawhtC24YKxhr2AG1oy1lDZP_lIdoQ3pKGy15eoMucD6QORVpG1GN0wUQriORig75_Kos94TjhW7wHP0PCFOtgf4cMJ8hzDBkydgHPcJz3brdkfLf4nU4u41kXB6HkChpwdy7sKlggTZBiwNrPe42ZrnsHMMVVpVVHW-vWAJeINc6l1tTJ4jnFEk30uOwh6fn0uiZTzcWj-wYWmxhKit7XZUlO-yfo0aR9hsv7eYs-v72-vXrf3Hx89-HqzU1jWiVKI1TLO1vfCzhTRoO2k-qkANaNnVJWGS71RAUd6TiOndQ9aEOZFH2viejA8i16cdat_X1dIJfh6LIB73WAuOSByk5JRZhg_4EqyXlPu7aiz_9CD3FJoV5kpYToCa_sFtEzZVLMOcE0zMkddToNlAyrFYazFYZqhWG1wrA28exeeRmPYH-d-PnxFWBnINdU2EH6o_Q_VX8Aol7AtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675590376</pqid></control><display><type>article</type><title>Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>El-Darouti, Mohammad A. ; Hegazy, Rehab A. ; Abdel Hay, Rania M. ; El Hawary, Marwa S. ; Tawdy, Amira M. ; Fawzy, Marwa M. ; Rashed, Laila A.</creator><creatorcontrib>El-Darouti, Mohammad A. ; Hegazy, Rehab A. ; Abdel Hay, Rania M. ; El Hawary, Marwa S. ; Tawdy, Amira M. ; Fawzy, Marwa M. ; Rashed, Laila A.</creatorcontrib><description>T helper (Th)1 insufficiency was recently found to be related to the pathogenesis of pemphigus vulgaris (PV). Decreased Th1 response was particularly noticed in the early stages of PV. Therefore, administration of interferon alpha in the early stages of aggressive PV may lead to rapid control of the acute stage of the disease. Our aim was to evaluate the role of interferon alpha in the treatment of PV. 30 patients with acute severe PV (>60 % affection) and 30 age and sex-matched healthy subjects were included in this RCT. Patients were randomly divided into two groups (A and B). Group B patients received interferon retard (one subcutaneous injection/week for 4 weeks) in addition to our protocol for the treatment of PV (systemic pulse corticosteroids/cyclophosphamide in combination with sulphasalazine and pentoxifylline) that was administered to all the included patients. IFN-γ and IL-4 were estimated by ELISA before treatment, after 4 weeks and at the end of the study duration (12 weeks). Clinical assessment was done by PAAS on a biweekly basis. All PV patients showed significantly (
P
< 0.001) elevated levels of IL-4 and significantly (
P
< 0.001) depressed mean concentration of IFN-γ as compared with healthy controls. Twelve weeks after therapy both groups showed significant improvement in their mean PAAS being more evident and more rapid in group B. IFN-γ was elevated significantly and IL-4 was dropped significantly in group B patients in comparison to group A (
P
< 0.001). As a conclusion, interferon therapy in severe PV could achieve a more prompt and better clinical response.</description><identifier>ISSN: 0340-3696</identifier><identifier>EISSN: 1432-069X</identifier><identifier>DOI: 10.1007/s00403-014-1522-2</identifier><identifier>PMID: 25450635</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Cyclophosphamide - therapeutic use ; Dermatology ; Drug Therapy, Combination ; Enzyme-Linked Immunosorbent Assay ; Female ; Glucocorticoids - therapeutic use ; Hot Clinical Study ; Humans ; Immunologic Factors - therapeutic use ; Immunosuppressive Agents - therapeutic use ; Interferon-alpha - therapeutic use ; Interferon-gamma - blood ; Interleukin-4 - blood ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Pemphigus - drug therapy ; Pemphigus - immunology ; Pentoxifylline - therapeutic use ; Phosphodiesterase Inhibitors - therapeutic use ; Recombinant Proteins - therapeutic use ; Sulfasalazine - therapeutic use ; Th1 Cells - immunology ; Th2 Cells - immunology</subject><ispartof>Archives of Dermatological Research, 2015-05, Vol.307 (4), p.299-307</ispartof><rights>Springer-Verlag Berlin Heidelberg 2014</rights><rights>Springer-Verlag Berlin Heidelberg 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-57438d040e327caeadf7865e28b877d7c36af151b1bbb86a9eac126599a058ed3</citedby><cites>FETCH-LOGICAL-c475t-57438d040e327caeadf7865e28b877d7c36af151b1bbb86a9eac126599a058ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00403-014-1522-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00403-014-1522-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25450635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Darouti, Mohammad A.</creatorcontrib><creatorcontrib>Hegazy, Rehab A.</creatorcontrib><creatorcontrib>Abdel Hay, Rania M.</creatorcontrib><creatorcontrib>El Hawary, Marwa S.</creatorcontrib><creatorcontrib>Tawdy, Amira M.</creatorcontrib><creatorcontrib>Fawzy, Marwa M.</creatorcontrib><creatorcontrib>Rashed, Laila A.</creatorcontrib><title>Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial</title><title>Archives of Dermatological Research</title><addtitle>Arch Dermatol Res</addtitle><addtitle>Arch Dermatol Res</addtitle><description>T helper (Th)1 insufficiency was recently found to be related to the pathogenesis of pemphigus vulgaris (PV). Decreased Th1 response was particularly noticed in the early stages of PV. Therefore, administration of interferon alpha in the early stages of aggressive PV may lead to rapid control of the acute stage of the disease. Our aim was to evaluate the role of interferon alpha in the treatment of PV. 30 patients with acute severe PV (>60 % affection) and 30 age and sex-matched healthy subjects were included in this RCT. Patients were randomly divided into two groups (A and B). Group B patients received interferon retard (one subcutaneous injection/week for 4 weeks) in addition to our protocol for the treatment of PV (systemic pulse corticosteroids/cyclophosphamide in combination with sulphasalazine and pentoxifylline) that was administered to all the included patients. IFN-γ and IL-4 were estimated by ELISA before treatment, after 4 weeks and at the end of the study duration (12 weeks). Clinical assessment was done by PAAS on a biweekly basis. All PV patients showed significantly (
P
< 0.001) elevated levels of IL-4 and significantly (
P
< 0.001) depressed mean concentration of IFN-γ as compared with healthy controls. Twelve weeks after therapy both groups showed significant improvement in their mean PAAS being more evident and more rapid in group B. IFN-γ was elevated significantly and IL-4 was dropped significantly in group B patients in comparison to group A (
P
< 0.001). As a conclusion, interferon therapy in severe PV could achieve a more prompt and better clinical response.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dermatology</subject><subject>Drug Therapy, Combination</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Hot Clinical Study</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-gamma - blood</subject><subject>Interleukin-4 - blood</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Pemphigus - drug therapy</subject><subject>Pemphigus - immunology</subject><subject>Pentoxifylline - therapeutic use</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Sulfasalazine - therapeutic use</subject><subject>Th1 Cells - immunology</subject><subject>Th2 Cells - immunology</subject><issn>0340-3696</issn><issn>1432-069X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNksuKFDEUhoMoTtPOA7iRgBs3pblUkip3MowXGHDhCO6KVHKqO006KZPUQPtwPpsperwgCGaTnJwv_zlJfoSeUvKSEqJeZUJawhtC24YKxhr2AG1oy1lDZP_lIdoQ3pKGy15eoMucD6QORVpG1GN0wUQriORig75_Kos94TjhW7wHP0PCFOtgf4cMJ8hzDBkydgHPcJz3brdkfLf4nU4u41kXB6HkChpwdy7sKlggTZBiwNrPe42ZrnsHMMVVpVVHW-vWAJeINc6l1tTJ4jnFEk30uOwh6fn0uiZTzcWj-wYWmxhKit7XZUlO-yfo0aR9hsv7eYs-v72-vXrf3Hx89-HqzU1jWiVKI1TLO1vfCzhTRoO2k-qkANaNnVJWGS71RAUd6TiOndQ9aEOZFH2viejA8i16cdat_X1dIJfh6LIB73WAuOSByk5JRZhg_4EqyXlPu7aiz_9CD3FJoV5kpYToCa_sFtEzZVLMOcE0zMkddToNlAyrFYazFYZqhWG1wrA28exeeRmPYH-d-PnxFWBnINdU2EH6o_Q_VX8Aol7AtQ</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>El-Darouti, Mohammad A.</creator><creator>Hegazy, Rehab A.</creator><creator>Abdel Hay, Rania M.</creator><creator>El Hawary, Marwa S.</creator><creator>Tawdy, Amira M.</creator><creator>Fawzy, Marwa M.</creator><creator>Rashed, Laila A.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20150501</creationdate><title>Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial</title><author>El-Darouti, Mohammad A. ; Hegazy, Rehab A. ; Abdel Hay, Rania M. ; El Hawary, Marwa S. ; Tawdy, Amira M. ; Fawzy, Marwa M. ; Rashed, Laila A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-57438d040e327caeadf7865e28b877d7c36af151b1bbb86a9eac126599a058ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dermatology</topic><topic>Drug Therapy, Combination</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Hot Clinical Study</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-gamma - blood</topic><topic>Interleukin-4 - blood</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Pemphigus - drug therapy</topic><topic>Pemphigus - immunology</topic><topic>Pentoxifylline - therapeutic use</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Sulfasalazine - therapeutic use</topic><topic>Th1 Cells - immunology</topic><topic>Th2 Cells - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Darouti, Mohammad A.</creatorcontrib><creatorcontrib>Hegazy, Rehab A.</creatorcontrib><creatorcontrib>Abdel Hay, Rania M.</creatorcontrib><creatorcontrib>El Hawary, Marwa S.</creatorcontrib><creatorcontrib>Tawdy, Amira M.</creatorcontrib><creatorcontrib>Fawzy, Marwa M.</creatorcontrib><creatorcontrib>Rashed, Laila A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Archives of Dermatological Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Darouti, Mohammad A.</au><au>Hegazy, Rehab A.</au><au>Abdel Hay, Rania M.</au><au>El Hawary, Marwa S.</au><au>Tawdy, Amira M.</au><au>Fawzy, Marwa M.</au><au>Rashed, Laila A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial</atitle><jtitle>Archives of Dermatological Research</jtitle><stitle>Arch Dermatol Res</stitle><addtitle>Arch Dermatol Res</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>307</volume><issue>4</issue><spage>299</spage><epage>307</epage><pages>299-307</pages><issn>0340-3696</issn><eissn>1432-069X</eissn><abstract>T helper (Th)1 insufficiency was recently found to be related to the pathogenesis of pemphigus vulgaris (PV). Decreased Th1 response was particularly noticed in the early stages of PV. Therefore, administration of interferon alpha in the early stages of aggressive PV may lead to rapid control of the acute stage of the disease. Our aim was to evaluate the role of interferon alpha in the treatment of PV. 30 patients with acute severe PV (>60 % affection) and 30 age and sex-matched healthy subjects were included in this RCT. Patients were randomly divided into two groups (A and B). Group B patients received interferon retard (one subcutaneous injection/week for 4 weeks) in addition to our protocol for the treatment of PV (systemic pulse corticosteroids/cyclophosphamide in combination with sulphasalazine and pentoxifylline) that was administered to all the included patients. IFN-γ and IL-4 were estimated by ELISA before treatment, after 4 weeks and at the end of the study duration (12 weeks). Clinical assessment was done by PAAS on a biweekly basis. All PV patients showed significantly (
P
< 0.001) elevated levels of IL-4 and significantly (
P
< 0.001) depressed mean concentration of IFN-γ as compared with healthy controls. Twelve weeks after therapy both groups showed significant improvement in their mean PAAS being more evident and more rapid in group B. IFN-γ was elevated significantly and IL-4 was dropped significantly in group B patients in comparison to group A (
P
< 0.001). As a conclusion, interferon therapy in severe PV could achieve a more prompt and better clinical response.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>25450635</pmid><doi>10.1007/s00403-014-1522-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-3696 |
| ispartof | Archives of Dermatological Research, 2015-05, Vol.307 (4), p.299-307 |
| issn | 0340-3696 1432-069X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1687670252 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Cyclophosphamide - therapeutic use Dermatology Drug Therapy, Combination Enzyme-Linked Immunosorbent Assay Female Glucocorticoids - therapeutic use Hot Clinical Study Humans Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Interferon-alpha - therapeutic use Interferon-gamma - blood Interleukin-4 - blood Male Medicine Medicine & Public Health Middle Aged Pemphigus - drug therapy Pemphigus - immunology Pentoxifylline - therapeutic use Phosphodiesterase Inhibitors - therapeutic use Recombinant Proteins - therapeutic use Sulfasalazine - therapeutic use Th1 Cells - immunology Th2 Cells - immunology |
| title | Study of T helper 1 and T helper 2 responses in pemphigus vulgaris patients receiving interferon alpha 2a injections in addition to a standard protocol therapy: a randomized controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A59%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Study%20of%20T%20helper%201%20and%20T%20helper%202%20responses%20in%20pemphigus%20vulgaris%20patients%20receiving%20interferon%20alpha%202a%20injections%20in%20addition%20to%20a%20standard%20protocol%20therapy:%20a%20randomized%20controlled%20trial&rft.jtitle=Archives%20of%20Dermatological%20Research&rft.au=El-Darouti,%20Mohammad%20A.&rft.date=2015-05-01&rft.volume=307&rft.issue=4&rft.spage=299&rft.epage=307&rft.pages=299-307&rft.issn=0340-3696&rft.eissn=1432-069X&rft_id=info:doi/10.1007/s00403-014-1522-2&rft_dat=%3Cproquest_cross%3E1687670252%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1675590376&rft_id=info:pmid/25450635&rfr_iscdi=true |